Clinical Study
Testing an Inhaled Study Drug Treprostinil for People with Progressive Pulmonary Fibrosis
Progressive Pulmonary Fibrosis is a disease scarring the lungs causing shortness of breath. The disease worsens over time. This study will test an inhaled (to breathe in) study drug called Treprostinil to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with inhaled Treprostinil or placebo. The placebo looks like the study drug but does not have the medication. Being in the study requires 8 in-person study visits at the study clinic for up to 58 weeks. Medical tests will be done to track the health of participants.
For more information contact:
Heather Hammerschmidt
heather.hammerschmidt@hsc.utah.edu
18015815811
IRB#: IRB_00173081
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2024-03-13 06:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18 years and older
- Diagnosis of Progressive Pulmonary Fibrosis
- On nintedanib or pirfenidone for 90 days before being in the study and plan to continue to be on that drug during the study
- Not on nintedanib or pirfenidone for 90 days before being in the study and not planning to start either drug during the study
- Agree to use specific birth control
Exclusion Criteria:
- Pregnant or breastfeeding
- Diagnosis of Idiopathic Pulmonary Fibrosis
Will I be paid for my time?
Yes